The in vivo SPECT/CT scans of 111In-labeled targeted nanoparticles and 111In-labeled untargeted nanoparticle in tumor bearing mice revealed a modest positive impact on prostate cancer localization due to active targeting made by conjugating PSMA to nanoparticles than untargeted nanoparticles. This evidence concerns the gene FOLH1 and prostate cancer.